Gynecomastia in Men: Causes, the Pinch Test and When You Do Not Need Surgery

Gynecomastia is growth of real breast gland tissue in a male — not fat. It is a symptom with a cause, so the first step is finding that cause, not booking an operation. Gynecomastia itself is not cancer; but a firm, one-sided lump in a man is not automatically gynecomastia, which is why the red flags on this page come before everything else. Male breast cancer is rare — up to 1% of all breast cancers — and unilateral enlargement is its important differential (Mannix, 2024; Faridi, 2025).

I am an andrologist, not a plastic surgeon. Notice what happens when you search this word: a large share of what you are shown is sold by somebody who removes chests for a living, so those pages all end in the same place. Mine does not have to — which also obliges me to be straight about the men for whom an operation genuinely is the answer.

Spelled gynaecomastia in British usage, called gyno and man boobs elsewhere — none of those names tells you which of four very different situations you are in.

Before any of the rest of it, the short list that changes what you do today. Gynecomastia itself is not cancer, and the overwhelming majority of men reading this have something benign with a findable cause. But male breast cancer is the one diagnosis that cannot wait for a watchful-waiting plan, and it hides in exactly the presentation men assume is harmless.

If none of that applies to you, good — the rest of this page is about working out which of four very different situations you are actually in, and what each one needs.

Those six decide almost every consultation I do.

Quick facts

• Gynecomastia is benign proliferation of the glandular tissue of the male breast, with a reported prevalence of 32% to 65% depending on age and the criteria used (Kanakis, 2019).
• Palpable breast tissue was present in 36% of 306 healthy adult men; a diameter greater than 5 cm was distinctly unusual (Nuttall, 1979).
• Medicines cause an estimated 10% to 25% of all cases (Deepinder, 2012); a separate review puts drugs at about 20% (Bowman, 2012).
• Proper investigation in adults reveals an underlying pathology in about 45% to 50% of cases (Kanakis, 2019; Billa, 2021).
• It affects between one and two thirds of middle-aged men (Baumgarten, 2018), and is not a premalignant condition (Kanakis, 2019).

What gynecomastia actually is — and what it is not

Gynecomastia is the benign proliferation of glandular breast tissue in men (Kanakis, 2019), the most common breast condition in males (Cuhaci, 2014), and usually bilateral (Faridi, 2025).

The mechanism is one sentence: breast tissue grows when the stimulating effect of oestrogen outweighs the inhibiting effect of androgen at the breast itself (Leung, 2017) — a rise in the ratio of oestrogen to androgen activity (Gikas, 2006), from more oestrogen, less androgen, or both (Cuhaci, 2014). Fat is no bystander. In young men, idiopathic gynecomastia appears to result from androgen resistance and, in part, from increased aromatisation because of increased adiposity (Yazici, 2010) — aromatase being the enzyme fat uses to turn testosterone into oestrogen.

Now the sentence a surgical page can never quite afford to write: gynecomastia is a manifestation of disease, not a diagnosis in itself (Faridi, 2025). Removing a finding without identifying its cause is not treatment. It is tidying up.

It is also, very often, a normal finding. Nuttall found palpable breast tissue in 36% of 306 healthy men, rising to 57% over age 44, and concluded that this prevalence must be weighed before blaming a drug or a disease (Nuttall, 1979). It peaks three times across life: infancy, puberty, old age (Billa, 2021). But do not read “common” as “innocent” — physiological gynecomastia accounts for almost 25% of cases (Sansone, 2017), and 45% to 50% of adult cases turn out to have a pathology behind them (Kanakis, 2019).

Gynecomastia or chest fat? The pinch test, and the table nobody publishes

Step one is ruling out pseudogynecomastia by careful history and physical examination (Johnson, 2009). Pseudogynecomastia — lipomastia — is increased aggregation of fatty tissue in the male breast producing a female appearance, either after massive weight loss or as plain adipose tissue (Ziegler, 2018). The guideline is blunt about the job: breast examination should confirm palpable glandular tissue, to separate gynecomastia from lipomastia and rule out a malignant breast tumour (Kanakis, 2019). Gland feels like a firm or rubbery, discrete, subareolar ridge — symmetrical, freely movable, not stuck to skin or to anything underneath (Leung, 2017).

How to do the pinch test. Lie flat. Put thumb and index finger wide apart at the outer edge of the breast and walk them slowly inwards, pinching gently. Fat stays soft and uniform and you never meet an edge. Gland closes the pinch onto something with a border — a firm rubbery disc under the areola that moves and whose boundary you can trace. That manoeuvre is how I examine men, not a protocol from a trial; what the guideline requires is the finding itself (Kanakis, 2019).

What you are checking	True gynecomastia (gland)	Pseudogynecomastia (fat)
What it actually is	Benign proliferation of glandular breast tissue (Kanakis, 2019; Dickson, 2012)	Increased aggregation of fatty tissue in the male breast (Ziegler, 2018)
How it feels	Firm or rubbery, discrete ridge directly under the areola; symmetrical, freely movable, not adherent to skin (Leung, 2017)	Soft and uniform all the way in, the same texture as fat elsewhere; no discrete edge (Dr Shah, clinical description)
Pain or tenderness	Common enough that trials of drug-induced cases count breast pain as a separate outcome alongside the gynecomastia itself (Tsuboi, 2025; Viani, 2012)	Usually not tender (Dr Shah, clinical observation — not measured in the cited studies)
On ultrasound	Florid disease shows a disc-shaped hypoechoic area under the areola; echogenicity rises as fibrosis develops (Billa, 2021)	Ultrasound is used precisely to separate the two, and to stage the gland (Stoian, 2026)
Does losing weight fix it?	No — the tissue is gland, not adipose (Kanakis, 2019). In a prospective series of 536 adolescent boys, those who developed it were actually lighter, with a lower Quetelet index — and, in the same analysis, had significantly lower free testosterone and higher testosterone-oestrogen binding globulin (Biro, 1990)	Yes — it is fat, and it behaves like fat (Ziegler, 2018)
Do the blood tests still matter?	Yes — underlying pathology is found in 45% to 50% of adult cases (Kanakis, 2019; Billa, 2021)	Yes. Hypogonadism was present in 35.1% of men with pseudogynecomastia alone, and the authors warn that signs of hypogonadism must be evaluated carefully in exactly these men (Yazici, 2010)

Read that last row twice, because it contradicts what the AI answer tells you: “it’s only fat, your hormones are fine” was wrong in more than a third of the men in that study.

Now the sentence the surgical pages made famous and left half-finished. They are right that exercise will not remove established gland. But “exercise will not remove it” and “therefore you need an operation” are different claims. Pubertal cases resolve on their own (Kanakis, 2019); drug-induced cases can reverse when the drug stops (Sansone, 2017); pathological cases resolve when the pathology is treated (Dickson, 2012). And the operation these reviews recommend combines excision of gland with liposuction of fat (Fagerlund, 2015; Hurwitz, 2022) — a design that only makes sense because gland and fat frequently sit in the same chest — my inference, not a figure either paper reports.

Pubertal gynecomastia: why most of the boys reading this are fine

If you are fifteen, frightened, and hiding inside a loose shirt, this section is yours.

Gynecomastia of puberty affects approximately 50% of mid-pubertal boys and resolves spontaneously within 24 months in more than 90% of cases (Kanakis, 2019). It affects up to 50% of adolescents of the relevant age, with rising prevalence in recent years (Shi, 2024), typically appearing at 13 to 14 years, mostly idiopathic and self-limited (Berger, 2022).

One study followed 536 boys aged 10 to 15 every six months for three years. Prevalence was 48.5%; bilateral in 55%, left-sided in 19%, right-sided in 26%; recorded at a single visit in most boys. About half of adolescent boys have transient gynecomastia, usually lasting less than a year (Biro, 1990).

Two details from it earn their place. The affected boys were lighter, with a lower Quetelet index, than the unaffected — so this is not a fat problem. And oestradiol, testosterone, the oestrogen-to-testosterone ratio and DHEAS showed no significant differences between the groups (Biro, 1990), which is why a hormone panel on an otherwise well mid-pubertal boy usually tells you nothing.

Reassurance is all that is necessary for most physiological cases (Leung, 2017) — but reassurance is not dismissal, and psychological impairment is common in these adolescents (Berger, 2022).

Newborns get it too, usually resolving within the first year (Kanakis, 2019). The standard explanation is the mother’s oestrogen still circulating in the baby, a mechanism not spelled out in the papers cited here.

The adolescent I do not relax about

Where I do not relax is the boy with something else alongside the chest. A 15-year-old with two years of bilateral breast growth, an undescended testis, low testosterone and raised gonadotrophins turned out to have 46,XX ovotesticular disorder of sex development on karyotyping (Gaur, 2025).

Among 135 young men referred to a tertiary centre for breast enlargement, Klinefelter syndrome was diagnosed in 52% and idiopathic gynecomastia in 23% (Yazici, 2010) — a referral-centre figure, not a community rate, but fair warning that gynecomastia persisting into the twenties is a different animal. Gynecomastia with no sperm in the semen is a specific indication for karyotype analysis (Yazici, 2010).

Drug-induced gynecomastia — and why the answer is switching, not stopping

Medicines cause an estimated 10% to 25% of all cases (Deepinder, 2012); a separate review puts drugs at about 20% (Bowman, 2012). Up to one man in four — the group with the best outcome and the least attention.

Here is what almost nobody writes down. Treating the underlying disease or discontinuing the medication might resolve the gynecomastia (Sansone, 2017). Stopping contributing medications and treating underlying disease are the mainstay of treatment (Dickson, 2012), and treatment may simply mean switching to an alternative agent — surgery or irradiation come in only when the causative drug cannot be discontinued (Bowman, 2012). What the guideline recommends after you stop the substance is watchful waiting (Kanakis, 2019).

Drug or class	How it is thought to do it	Strength of the association
Anti-androgens — bicalutamide, and the androgen-receptor pathway inhibitors enzalutamide, apalutamide, darolutamide	Block androgen action, shifting the testosterone-to-oestradiol ratio (Trinchieri, 2021)	Definite (Deepinder, 2012). Odds raised about 17-fold across 6 trials and 9,599 men (Trinchieri, 2021); ARPI monotherapy raises risk more than five-fold against ADT alone (Tsuboi, 2025), with reported rates of 34% to 55% (Vibert, 2025)
Spironolactone	Blocks androgen action and shifts the same ratio (Trinchieri, 2021)	Definite (Deepinder, 2012). Odds raised about 8-fold across 14 trials (Trinchieri, 2021)
5-alpha-reductase inhibitors — finasteride, dutasteride	Alter the androgen-to-oestrogen balance (Trinchieri, 2021)	Definite (Deepinder, 2012). Odds raised 1.77-fold across 34,860 participants (Trinchieri, 2021)
Cimetidine (older heartburn drug)	Anti-androgenic effect	Definite (Deepinder, 2012); listed among the less common drug causes (Bowman, 2012)
Ketoconazole	Interferes with steroid synthesis	Definite (Deepinder, 2012)
hCG, growth hormone, oestrogens, GnRH analogues	Direct hormonal stimulation of the breast or the gonads	Definite (Deepinder, 2012)
HIV medicines — protease inhibitors, NRTIs, efavirenz	Not fully established	Protease inhibitors and NRTIs are among the most common drug causes (Bowman, 2012); efavirenz is probably associated (Deepinder, 2012)
Antipsychotics — risperidone and the first-generation agents	Raised prolactin (Trinchieri, 2021)	Probable (Deepinder, 2012). Odds 4.32-fold higher with risperidone than quetiapine across 3 trials (Trinchieri, 2021); first-generation agents a less common cause (Bowman, 2012)
Calcium channel blockers — verapamil, nifedipine	Not established	Probable (Deepinder, 2012); verapamil listed among the less common causes (Bowman, 2012)
Omeprazole and the PPIs	Not established	Probable (Deepinder, 2012)
Anabolic steroids	Excess androgen is aromatised to oestrogen	Probable (Deepinder, 2012)
Alcohol and opioids; alkylating chemotherapy	Multiple, including gonadal toxicity	Probable (Deepinder, 2012). Illicit drug use is a recognised non-physiological cause (Dickson, 2012)
Supplements and herbal products	Variable, often unlabelled ingredients	Named as a cause of non-physiological gynecomastia alongside medications and illicit drugs (Dickson, 2012)

Two pieces of honesty about that table. Most reported drug–gynecomastia associations rest on poor-quality evidence (Deepinder, 2012) — hence a column separating “definite” from “probable” rather than forty names in one frightening list. And on what I left out: longer lists elsewhere include digoxin, ACE inhibitors, isoniazid, metoclopramide and methotrexate, absent here because the review I work from does not grade them as definite or probable — not because they are proven harmless.

One critical caveat, and it is the guideline’s, not mine. Finding an obvious reason in an adult, including a medicine known to cause it, should not preclude a detailed investigation (Kanakis, 2019). On steroids, the mechanism is the part that matters: androgen taken from outside the body is aromatised to oestrogen (Deepinder, 2012) — which is how a lean, heavily muscled man with almost no body fat still grows a firm disc under the nipple.

When gynecomastia is a symptom of something else

Two figures sit either side of this and you should have both. Leung’s review states plainly that the majority of cases are physiological and need nothing beyond reassurance (Leung, 2017).

Against that, investigation in adults reveals an underlying pathology in about 45% to 50% of cases — medications, systemic disease, obesity, endocrinopathies or malignancy (Billa, 2021; Kanakis, 2019) — including endocrine disorders and previously undetected systemic disease (Rosellen, 2025).

Both are true. Which one applies to you turns largely on your age, and on whether anybody has actually looked. Here is what that looking is for.

• Low testosterone, because gynecomastia often follows androgen deficiency (Sansone, 2017), and testosterone is offered where deficiency is proven (Kanakis, 2019) — if that is you, the other symptoms of low testosterone are usually there once you look.
• Liver failure and chronic kidney disease (Sansone, 2017), along with cirrhosis and renal insufficiency (Dickson, 2012).
• Thyroid disease, which is why TSH and free T4 sit in the panel (Faridi, 2025).
• Klinefelter syndrome, which is why chromosomal analysis is on the list (Faridi, 2025; Yazici, 2010).
• Tumours, rarely (Dickson, 2012) — unexplained gynecomastia should prompt laboratory workup, then imaging for hormone-producing cancers (Baumgarten, 2018).

Why it seems commoner now

A systematic review proposes endocrine-disrupting chemicals — bisphenols, phthalates, polycyclic aromatic hydrocarbons — as an environmental risk factor, while conceding it rests on partial experimental evidence with unclear mechanisms (Wang, 2026). A hypothesis worth watching, not an answer.

One further pattern I name without a citation, because my reference list does not cover it: refeeding gynecomastia, appearing as a man regains weight after significant undernutrition. That is my clinical observation.

What actually brings men to my clinic: intimacy, fertility and the fear of low testosterone

Almost nothing written about this word covers the part that actually makes a man pick up the phone. It is rarely the chest by itself. It is what the chest has started to cost him.

Taking your shirt off in front of someone

This is the thing men say last, usually at the door, usually phrased to sound casual. They have stopped undressing in front of a partner. They keep a t-shirt on in bed. They turn the light off first, or they find a reason not to start at all — and several months of that quietly becomes a sexless marriage that neither person can explain out loud.

I want to say plainly that this is not vanity, and it is not a minor complaint. The published version of it is that psychological impairment is common in adolescents with gynecomastia (Berger, 2022). The adult version is not in my reference list at all, and what I have written above is my clinical observation across years of these consultations rather than a trial finding. But it is the single commonest reason a grown man finally comes in, and I am not leaving it off a page about his chest because the literature has not got round to measuring it.

“Does this mean my testosterone is low?”

This is the question they arrive holding, and the honest answer is: not on its own — but do not let anyone wave it away either.

In 536 boys, total testosterone, oestradiol and the oestrogen-to-testosterone ratio did not differ between those with gynecomastia and those without — yet free testosterone was significantly lower and binding globulin significantly higher in the affected group (Biro, 1990). A normal total testosterone therefore does not close the question, which is exactly why free testosterone belongs on the form.

And hypogonadism turned up in 35.1% of men whose enlargement was pure fat rather than gland (Yazici, 2010) — a third of the men who had been told it was “just fat”. Gynecomastia often follows androgen deficiency (Sansone, 2017), and where deficiency is proven, testosterone is offered (Kanakis, 2019).

So the fear is not irrational. It is testable. The symptoms of low testosterone are usually sitting there alongside it, once somebody actually asks.

The erection worry that travels with it

Two different things arrive wearing the same coat here, and separating them is most of the consultation.

If testosterone is genuinely low, that is measurable and it has a treatment pathway — the chest and the erection difficulty are then two symptoms of one cause, not two diseases. If the hormones come back normal, which is the commoner result, what is interfering is usually the anxiety itself: a man braced for his partner’s reaction, monitoring himself instead of being present.

No paper in my reference list measures that, so I will label it for what it is — my clinical observation. It is also, in my experience, the version that improves fastest, because it starts improving the moment somebody explains what is actually happening.

Fertility — where this stops being about appearance

This is the connection that matters most and gets written about least, and unlike the paragraphs above it is properly evidenced.

I quoted the figure earlier and it belongs here too: among 135 young men referred to a tertiary centre for breast enlargement, Klinefelter syndrome was diagnosed in 52% (Yazici, 2010). That is a referral-centre rate rather than a community one — but it is a striking number, and for a good share of those men the breast tissue was the first thing anybody had noticed. Gynecomastia together with no sperm in the semen is a specific indication for karyotype analysis (Yazici, 2010).

Set that beside the guideline’s insistence on examining the testes with ultrasound backup (Kanakis, 2019) and the shape of it is clear enough. For a subset of men, the chest is the visible end of a fertility problem nobody has gone looking for. If you are in your twenties or thirties, have had this a while, and have never had a semen analysis or a proper hormone panel, that is the gap worth closing — long before anyone books you a theatre slot.

What that consultation contains is below, so you can judge whether you have had one.

The workup: what I examine, and what I actually test

The evaluation does two jobs — clarify the endocrine picture and exclude a neoplasm (Rosellen, 2025). The history covers onset and duration of the swelling, sexual development and function, and the administration or abuse of any substance associated with gynecomastia (Kanakis, 2019). Every tablet and gym supplement — bring the boxes.

The examination — where this page diverges from everybody else’s

Look for signs of under-virilisation or systemic disease, and confirm on breast examination whether there is genuinely palpable glandular tissue (Kanakis, 2019).

Then the recommendation that appears on almost no patient page in this search result: the examination must include the genitalia, to rule out a palpable testicular tumour and detect testicular atrophy — supported by testicular ultrasound, because detecting a testicular tumour by palpation alone has low sensitivity (Kanakis, 2019).

In fairness I should say how that recommendation is graded: the guideline itself rates it a strong recommendation on low-quality evidence (Kanakis, 2019). I hold it anyway, and I would rather tell you the grade than hide it — the scan costs very little, and the thing it is looking for is a testicular tumour. Basic evaluation covers the breast area and the genitals, with breast and testicular sonography (Faridi, 2025).

If you have been offered a chest operation and nobody has examined your testicles, you have not been assessed — and if you have felt a lump in the testicle yourself, that changes the urgency entirely.

The bloods

Testosterone, oestradiol, sex hormone binding globulin, LH, FSH, TSH, prolactin, hCG, alpha-fetoprotein, liver and renal function (Kanakis, 2019), with free T4, DHEA, free testosterone and chromosomal analysis added as indicated (Faridi, 2025) — the same disciplined male assessment I run for fertility, undertaken once physiological and drug-induced causes have been considered (Sansone, 2017).

Notice that hCG and alpha-fetoprotein are on that list, and that the guideline separately insists on examining the testes with ultrasound backup (Kanakis, 2019). Put the two together and you have the case the whole workup exists to catch: a young man whose new breast growth is the first sign of a hormone-producing testicular tumour. Joining those two recommendations is my reading, not the guideline’s wording.

Imaging, where examination is inconclusive

Ultrasound is generally preferred first-line — it separates gynecomastia from pseudogynecomastia, stages the gland and picks up suspicious features early, while mammography retains value in older patients or where cancer is suspected (Stoian, 2026). Gynecomastia appears as a subareolar opacity in nodular, dendritic or diffuse patterns (Billa, 2021).

Suspicious lesions go straight to core needle biopsy (Kanakis, 2019). If everything is normal, the diagnosis is idiopathic gynecomastia (Johnson, 2009) — a real answer, from a review candid that the evidence here is mainly observational.

Red flags: when this needs looking at now

Male breast cancer is rare — up to 1% of all breast cancers — but some data indicate its incidence is increasing, and men tend to present at a later stage than women (Mannix, 2024). Around 700 men a year are diagnosed with it in Germany, and unilateral gynecomastia is its important differential diagnosis (Faridi, 2025). Over-reassurance does more harm here than a frank paragraph.

Here is the list nobody in this search result has assembled.

Red flag	Why it matters
Hard, irregular or fixed lump	Benign gynecomastia forms a freely movable, non-adherent rubbery disc (Leung, 2017); breast cancer typically presents as an irregular mass (Mannix, 2024)
Skin dimpled, tethered or ulcerated	Benign gynecomastia is not adherent to skin or to underlying tissue (Leung, 2017)
Mass larger than 5 cm	Distinctly unusual even among healthy men with palpable breast tissue (Nuttall, 1979)
New one-sided enlargement in an adult	Gynecomastia is usually bilateral, and unilateral disease is where male breast cancer sits in the differential (Faridi, 2025)
Sitting off-centre to the nipple	Benign gynecomastia is concentric — a disc centred under the areola (Leung, 2017). A mass eccentric to the nipple is the one I will not watch and wait on — my practice, not a finding of the studies cited here
Growing quickly	Benign gynecomastia enlarges slowly. Rapid growth changes the question from what is causing this to what is this — my practice, not a finding of the studies cited here
Nipple discharge, or a lump in the armpit	I check both and escalate on either — my practice, not a finding of the studies cited here
Any solid mass, even a reassuring-looking one	Male breast cancer occasionally has a benign-appearing imaging phenotype, so most solid breast masses in men require a tissue diagnosis (Mannix, 2024)

Two honest complications. Position settles nothing, because male breast cancer also favours the subareolar breast (Mannix, 2024). And one-sidedness is not alarming in a teenager, where it was unilateral in 45% of affected boys (Biro, 1990).

When NOT to operate for gynecomastia — and when surgery is genuinely right

Five situations where an operation is the wrong next step, and the one where it is genuinely right.

Situation	Why an operation is not the next step	What is
The cause has not been identified	Gynecomastia is a manifestation of disease, not a diagnosis (Faridi, 2025), and even an obvious explanation should not preclude detailed investigation (Kanakis, 2019)	Workup first; unexplained cases need labs then imaging for hormone-producing cancers (Baumgarten, 2018)
A boy inside the pubertal window	More than 90% resolve spontaneously within 24 months (Kanakis, 2019); most last under a year (Biro, 1990)	Examine once, reassure (Leung, 2017), review. Surgery is reserved for severe cases towards the end of puberty (Berger, 2022)
The causative drug is still being taken	Stopping or switching the medicine may resolve it (Sansone, 2017; Bowman, 2012)	Change the drug with the prescriber, then watchful waiting (Kanakis, 2019)
It is pseudogynecomastia	Confirming palpable glandular tissue is the point of the breast examination (Kanakis, 2019); ruling out pseudogynecomastia is step one (Johnson, 2009)	Fat loss. After massive weight loss, residual fat and skin excess vary enormously (Ziegler, 2018) — a different operation with a different aim
Established gland that has never had a medical trial	In my clinic a good number of these men settle enough once the hormonal driver is treated that they no longer want an operation — my clinical observation, not trial evidence, and it runs against the guideline position in the row below	A supervised trial first: an aromatase inhibitor off-label, testosterone corrected where it is genuinely low, and structured upper-body strength work. Reassess before consenting to anything
A true, discrete lump — or gland that has had a proper medical trial and not shifted	—	Operate. This is where I refer, and it is also the guideline position: surgical treatment is the therapy of choice for patients with long-lasting gynecomastia (Kanakis, 2019)

The reason that last row exists sits in the imaging: early disease is florid, and as it persists it turns fibrous — echogenicity rises as fibrosis develops (Billa, 2021). Once that fibrosis is established, hormonal treatment works less well — that is my clinical reasoning from how these men respond, not a treatment finding of the imaging study above, and I would rather label it than dress it in someone else’s citation. In clinic I work with about a year as the point where the conversation changes; that number is my working rule, not a figure from any trial in my reference list.

Less well is not the same as never, though, and that distinction is the whole reason I will still run a supervised medical trial before any man of mine signs a surgical consent form.

Where the drug cannot be stopped, prevention takes over: prophylactic tamoxifen cut gynecomastia incidence to 10% from 73% in men on bicalutamide (Vibert, 2025), with a number needed to treat of 1.56 against 3.4 for radiotherapy, though tamoxifen carried roughly six times the adverse effects (Viani, 2012). That belongs with the oncologist.

The operation, and the evidence behind it

The operation is well described. Excision of glandular tissue combined with liposuction gives the most consistent results with a low complication rate (Fagerlund, 2015), with options arranged across a modified Simon classification by severity (Hurwitz, 2022).

The best evidence here is a randomised trial: 140 men allocated to endoscopic lipolysis with liposuction or to traditional open excision, in which the endoscopic arm gave shorter operations, less bleeding, fewer complications and less pain, with no difference in recurrence or satisfaction at one year (Diao, 2025). That is the strongest single study on this page in either direction, and I am not going to bury it because it happens to be about an operation.

What I will say is what it does and does not settle. It compares two surgical techniques against each other — it does not test surgery against leaving things alone, or against treating the cause first.

For the older question of whether excision plus liposuction is the right operation at all, the evidence is weaker. That recommendation rests on a review of 17 studies, all non-randomised, all at high risk of bias, all rated very low quality by GRADE (Fagerlund, 2015) — a 2015 assessment of pre-2014 work, which by definition did not and could not rate the 2025 trial above.

Complications relate to delayed healing caused by excessive closure tension or by inadequate or inappropriate treatment (Hurwitz, 2022), and haematoma was the postoperative complication reported in the adolescent series below (Anderko, 2026).

Beyond that, here is what I tell my own patients to ask any surgeon before consenting — my list, not a complication rate from the papers cited here.

• Seroma
• Altered or lost nipple sensation
• Contour irregularity, or over-resection leaving a saucer deformity
• Visible scarring
• Recurrence
• How many of these operations they do in a year

A surgeon who answers all six without flinching is the one to have.

And if surgery is your answer, here is the pathway rather than a shrug. Get the cause worked up first, because operating on drug-induced disease without changing the drug invites it back. Then ask for a referral to a plastic or breast surgeon who does this operation regularly, take the imaging and blood results with you, and have the conversation about technique — the randomised evidence above favours the endoscopic liposuction approach on operating time, bleeding, pain and complications (Diao, 2025). I am happy to do the workup and write that referral; what I do not do is the operation itself, which is precisely why I have no reason to talk you into or out of it.

The study that argues against me

My reference list also holds a study that cuts against my emphasis, and you should have it. A retrospective series of 26 boys aged 10 to 17 reported bilateral disease in 77%, median age at surgery of 16, complications in 11.5%, no reoperations and high satisfaction at a median 4 out of 5 — concluding that this supports timely surgical intervention in adolescents with persistent gynecomastia causing aesthetic or psychological concern (Anderko, 2026).

I do not dispute it, and I want to represent its argument as its authors made it rather than as it suits me. They found that older adolescents were slightly less satisfied, and they read that as a reason to operate sooner in boys whose disease has already declared itself persistent — not as a caution against operating (Anderko, 2026).

On my side of it I would point only at the word persistent, and at the median age of 16, by which point the natural resolution window has run for most boys. That is a disagreement about when, not about whether — and on the whether, they are right.

On cost, men in Chennai are typically quoted ₹40,000 to ₹1,50,000 or more, with a compression garment for several weeks: market and practice observation, not trial data.

What actually shrinks gynecomastia: tablets, exercise and the GLP-1 question

Tablets, honestly

The European Academy of Andrology’s position is that the use of selective oestrogen receptor modulators, aromatase inhibitors and non-aromatisable androgens is not justified in general (Kanakis, 2019). That is a guideline saying these drugs lack the evidence, and I will not talk around it — least of all because what I do in clinic sits on the other side of it.

Against it sit three findings. Tamoxifen was used in most studies of pubertal gynecomastia and found effective, safe and with minimal side effects, so pharmacological intervention is appropriate in selected patients even though high-quality publications are lacking (Berger, 2022). Pubertal gynecomastia may safely be managed with anti-oestrogen treatment (Fagerlund, 2015). And where physiological gynecomastia persists and treatment becomes necessary, tamoxifen is the treatment of choice (Leung, 2017).

Now the other half of that honesty. Fagerlund’s review rated the studies it examined as non-randomised, at high risk of bias and very low quality by GRADE (Fagerlund, 2015); Berger’s own conclusion is that high-quality publications are lacking (Berger, 2022). So the tablet evidence and the older surgical evidence sit at a comparable level — that is the one standard I am applying throughout this page.

What I actually do — and the fact that it is off-label

My first move in an adult with real gland and no red flag is not a referral for excision. It is an aromatase inhibitor — letrozole — used off-label, alongside correcting testosterone where it is genuinely low, and structured upper-body strength work.

The reasoning is mechanical rather than trial-based. Gynecomastia is an imbalance between oestrogen and androgen at the breast (Leung, 2017; Gikas, 2006), and aromatisation of androgen into oestrogen is the step that feeds it (Deepinder, 2012) — so blocking that step addresses the driver instead of removing the result.

Three things you are owed plainly.

• It is off-label. Letrozole is not licensed for gynecomastia.
• The EAA guideline explicitly does not endorse this class (Kanakis, 2019).
• My reason for offering it anyway is how the men I treat actually respond — clinical observation, not evidence of the kind I have been holding everything else on this page to.

It needs supervision, monitoring and a defined stopping point. I keep this at class and mechanism level deliberately: I do not prescribe from a web page, and you should not source from one.

Testosterone, where it is genuinely low

Where hypogonadism is proven, testosterone is offered (Kanakis, 2019) — and it is worth testing properly rather than assuming, given that hypogonadism turned up in 35.1% of men whose enlargement was pure fat (Yazici, 2010). Correcting a real deficiency works on the same ratio the aromatase inhibitor does, from the other end. What this is emphatically not is a case for a man with normal levels taking testosterone: androgen from outside the body is aromatised to oestrogen (Deepinder, 2012), which is precisely how it makes the problem worse.

Timing is the whole game

Medical therapy is a florid-phase tool. Once the tissue is fibrous (Billa, 2021), tablets are asking soft-tissue chemistry to undo scar — which explains both why waiting is right early and why the tablets stopped working late.

Exercise, weight loss and training the chest

Exercise and weight loss work completely on the fat component (Ziegler, 2018), and losing body fat lowers the aromatisation driving oestrogen up in the first place (Yazici, 2010). They do not dissolve established gland. Both halves are true — and the second half is not a reason to skip the gym.

I put these men on structured upper-body strength work, chest and shoulders especially, for two reasons I will name as exactly what they are. Building the muscle underneath changes the contour and the way the chest sits, which is what most men are actually pointing at when they pull at their shirt. And losing the fat over it addresses the pseudo component and the aromatisation at the same time (Ziegler, 2018; Yazici, 2010).

Toning the chest is a contour and confidence gain sitting alongside the medical treatment — I am not going to tell you press-ups dissolve a disc of breast tissue.

And no supplement in my reference list treats gynecomastia — supplements appear in these papers as a cause of non-physiological gynecomastia (Dickson, 2012), never a cure.

The Ozempic question

Nobody in the top thirty pages answers this one. No trial in my reference list has tested a GLP-1 drug for gynecomastia and I will not pretend otherwise. From mechanism: these drugs cause weight loss, pseudogynecomastia is fat (Ziegler, 2018), so fat loss reduces the pseudo variety — while glandular tissue is not adipose (Kanakis, 2019) and stays. As surrounding fat disappears an existing gland can become more conspicuous.

Frequently asked questions

Can gynecomastia go away?

Often. Infant cases usually resolve within the first year and more than 90% of pubertal cases within 24 months (Kanakis, 2019); drug-induced cases may resolve once the responsible medicine is changed (Sansone, 2017). Long-standing fibrous disease does not (Billa, 2021). Never stop a prescribed medicine on your own to try this — some of the drugs on that list treat prostate cancer, HIV or serious psychiatric illness, and stopping them unsupervised is far more dangerous than the gynecomastia. The move is switching to an alternative agent, and that decision belongs with the doctor who prescribed it (Bowman, 2012).

At what age is gynecomastia most common?

Mid-puberty: around half of mid-pubertal boys (Kanakis, 2019; Shi, 2024), typically 13 to 14 years (Berger, 2022). There is a second rise with age — 57% of healthy men over 44 had palpable breast tissue (Nuttall, 1979).

What is the main cause of gynecomastia?

An imbalance between the stimulating effect of oestrogen and the inhibiting effect of androgen at the breast (Leung, 2017; Gikas, 2006). Commonest setting: normal puberty (Kanakis, 2019). Commonest treatable one: a medicine you already take (Deepinder, 2012).

What shrinks gynecomastia?

Removing the cause — treating the underlying disease, or changing the responsible medicine with your prescriber (Sansone, 2017; Dickson, 2012), and losing body fat, which lowers aromatisation (Ziegler, 2018; Yazici, 2010). Tamoxifen is used in selected cases despite weak evidence (Berger, 2022). My own approach in adults is an aromatase inhibitor, letrozole, off-label and supervised, with testosterone corrected where it is genuinely low and structured upper-body strength work alongside it. That is my clinical practice and observation — it is not licensed for this, and the EAA guideline does not endorse the class (Kanakis, 2019).

Can I remove gyno without surgery?

If it is fat, yes (Ziegler, 2018). If drug-induced, changing the drug can undo it — a decision for your prescriber, never one to take yourself (Sansone, 2017); if pubertal, time usually does (Kanakis, 2019). If it is established gland, the guideline answer is that surgery is the therapy of choice for long-lasting gynecomastia (Kanakis, 2019). Mine is less absolute: unless there is a true discrete lump, I would rather run a supervised off-label trial first — letrozole, testosterone corrected where low, upper-body strength work — and in my experience a fair number of men stop wanting the operation. Clinical observation, not trial evidence, and off-label.

How do I know if it’s gyno or chest fat?

By feel: true gynecomastia is a firm, discrete ridge under the areola, freely movable and not stuck to skin (Leung, 2017); fat is soft and uniform with no edge. Ultrasound settles doubtful cases (Stoian, 2026).

What is the pinch test for gynecomastia?

Pinching inwards from the outer edge of the breast towards the areola, feeling for a discrete disc with a traceable border rather than uniform softness — a screening way of confirming palpable glandular tissue (Kanakis, 2019), not a diagnosis.

Does gyno mean low testosterone?

Not by itself — but do not read that as “hormones are irrelevant”. In 536 boys, total testosterone, oestradiol and the oestrogen/testosterone ratio did not differ between those with and without gynecomastia — yet free testosterone was significantly lower and binding globulin significantly higher in those who had it, and the authors concluded exactly that (Biro, 1990). A normal total testosterone therefore does not close the question. Hypogonadism also appeared in 35.1% of men whose enlargement was pure fat (Yazici, 2010). Test properly rather than guess, and make sure free testosterone is on the form.

What is stage 4 gynecomastia?

It comes from surgical severity classifications — a modified Simon classification (Hurwitz, 2022), or the Gusenoff system after massive weight loss (Ziegler, 2018). They describe how much tissue and skin there is, not the cause; treatment depends on the underlying disease and the severity of symptoms (Faridi, 2025).

Can Ozempic cure gynecomastia?

No trial in my reference list has tested a GLP-1 drug for gynecomastia. Weight loss shrinks pseudogynecomastia because that is fat (Ziegler, 2018) but does not remove gland, which is not fat (Kanakis, 2019).

Is drug-induced gynecomastia reversible?

It can be: switching agent is the recognised treatment — not stopping treatment — with surgery or irradiation reserved for when the drug cannot be changed (Bowman, 2012), followed by watchful waiting (Kanakis, 2019). Most drug associations rest on poor-quality evidence (Deepinder, 2012), so it is not guaranteed.

The decent version of this conversation

You probably already know which of the four you are. A teenager inside the window needs examining once and reassuring properly. A man on spironolactone, finasteride, an anti-androgen or an antipsychotic needs a conversation with whoever prescribed it, then a wait. A man carrying weight needs the fat addressed and the gland assessed separately. A man with firm, long-standing, one-sided or growing tissue needs examining now — testicles first, chest second.

Nobody should be selling you an operation before they have felt your testes, read your medicine list and looked at your hormones. I sit further from the knife than most pages you will find on this word: unless there is a true discrete lump, an operation is not where I start, and I would rather treat the hormonal driver properly first and see what is left. I will also say plainly that the guideline disagrees with me — surgical treatment is the therapy of choice for long-lasting gynecomastia (Kanakis, 2019) — and that for a genuine established gland which has had its chance medically, the operation is the right call.

If you want it done properly and privately, come and have it looked at — bring every tablet and supplement you take, including the ones you would rather not mention. Most men who walk into my Chennai clinic expecting a surgery date leave with an explanation instead; that is my experience, not a published statistic. Some do go on to have the operation, and it is the right call when they do.

References

1. Anderko, 2026 — Clinical Characteristics and Surgical Outcomes of Adolescent Gynecomastia: A Retrospective Observational Study. Polski przeglad chirurgiczny. PMID: 41810498
2. Baumgarten, 2018 — Diagnosis and Management of Gynecomastia for Urologists. Current urology reports. PMID: 29774423
3. Berger, 2022 — Gynecomastia: A systematic review of pharmacological treatments. Frontiers in pediatrics. PMID: 36389365
4. Billa, 2021 — Imaging in gynecomastia. Andrology. PMID: 34033252
5. Biro, 1990 — Hormonal studies and physical maturation in adolescent gynecomastia. The Journal of pediatrics. PMID: 2137877
6. Bowman, 2012 — Drug-induced gynecomastia. Pharmacotherapy. PMID: 23165798
7. Cuhaci, 2014 — Gynecomastia: Clinical evaluation and management. Indian journal of endocrinology and metabolism. PMID: 24741509
8. Deepinder, 2012 — Drug-induced gynecomastia: an evidence-based review. Expert opinion on drug safety. PMID: 22862307
9. Diao, 2025 — A comparative study on the short-term and long-term efficacy of endoscopic lipolysis, liposuction, and traditional open excision in gynecomastia treatment. BMC endocrine disorders. PMID: 39984981
10. Dickson, 2012 — Gynecomastia. American family physician. PMID: 22534349
11. Fagerlund, 2015 — Gynecomastia: A systematic review. Journal of plastic surgery and hand surgery. PMID: 26051284
12. Faridi, 2025 — Diseases of the Male Breast: Gynecomastia and Breast Cancer. Deutsches Arzteblatt international. PMID: 40331995
13. Gaur, 2025 — Ovotesticular disorder of sex development presenting as gynecomastia in a phenotypic male adolescent: a case report and literature insights. Hormone molecular biology and clinical investigation. PMID: 41312604
14. Gikas, 2006 — The current management of gynecomastia: an update. International journal of fertility and women’s medicine. PMID: 17269591
15. Hurwitz, 2022 — Contemporary Management of Gynecomastia. Clinics in plastic surgery. PMID: 35367036
16. Johnson, 2009 — Gynecomastia: pathophysiology, evaluation, and management. Mayo Clinic proceedings. PMID: 19880691
17. Kanakis, 2019 — EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. PMID: 31099174
18. Leung, 2017 — Gynecomastia in Infants, Children, and Adolescents. Recent patents on endocrine, metabolic & immune drug discovery. PMID: 28260521
19. Mannix, 2024 — Imaging the Male Breast: Gynecomastia, Male Breast Cancer, and Beyond. Radiographics : a review publication of the Radiological Society of North America, Inc. PMID: 38752766
20. Nuttall, 1979 — Gynecomastia as a physical finding in normal men. The Journal of clinical endocrinology and metabolism. PMID: 429488
21. Rosellen, 2025 — [Gynecomastia in males : Diagnostics and treatment]. Urologie (Heidelberg, Germany). PMID: 41196306
22. Sansone, 2017 — Gynecomastia and hormones. Endocrine. PMID: 27145756
23. Shi, 2024 — Endocrine Hormones and Their Impact on Pubertal Gynecomastia. Journal of clinical medicine. PMID: 39797240
24. Stoian, 2026 — The Role of Ultrasound in Gynecomastia. Ultraschall in der Medizin (Stuttgart, Germany : 1980). PMID: 41956087
25. Trinchieri, 2021 — Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. PMID: 34933535
26. Tsuboi, 2025 — Incidence, Management, and Prevention of Gynecomastia and Breast Pain in Patients with Prostate Cancer Undergoing Antiandrogen Therapy: A Systematic Review and Meta-analysis of Randomized Controlled Trials. European urology open science. PMID: 39935942
27. Viani, 2012 — Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?. International journal of radiation oncology, biology, physics. PMID: 22704706
28. Vibert, 2025 — [Management strategies for gynecomastia in patients with prostate cancer treated with androgen receptor pathway inhibitors]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. PMID: 40561872
29. Wang, 2026 — Potential association between endocrine disrupting chemicals (EDCs) and gynecomastia: a systematic review based on partial experimental evidenceendocrine-disrupting chemicals. Frontiers in endocrinology. PMID: 41710411
30. Yazici, 2010 — Evaluation of breast enlargement in young males and factors associated with gynecomastia and pseudogynecomastia. Irish journal of medical science. PMID: 19495841
31. Ziegler, 2018 — Modified Treatment Algorithm for Pseudogynecomastia After Massive Weight Loss. Annals of plastic surgery. PMID: 29916894